Search research articles
Contact Us
Filters
Showing results (221-230 of 231) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2020
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila, Lori J Wirth, Thomas Ernst, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Head & Neck
|
February 12, 2025
Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report
Yen-Bo Lin, Hsiang-Wei Hu, An-Ko Chung, et al.
Oncoimmunology
|
January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal for Immunotherapy of Cancer
|
March 9, 2026
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers
Changhoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 10, 2023
Clinical practice consensus for the diagnosis and management of melanoma in Taiwan
Chiao-En Wu, Yi-Hua Liao, Cheng-Lin Wu, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 231) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2020
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Jaume Capdevila, Lori J Wirth, Thomas Ernst, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study
Ching-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Head & Neck
|
February 12, 2025
Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report
Yen-Bo Lin, Hsiang-Wei Hu, An-Ko Chung, et al.
Oncoimmunology
|
January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal for Immunotherapy of Cancer
|
March 9, 2026
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers
Changhoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 10, 2023
Clinical practice consensus for the diagnosis and management of melanoma in Taiwan
Chiao-En Wu, Yi-Hua Liao, Cheng-Lin Wu, et al.
Page
of 24